fbpx Skip to main content


CardiologyCardiomyopathyCardiovascular Risk ManagementHeart HealthTransthyretin Amyloid Cardiomyopathy

Tafamidis Reduces Cardiovascular Hospitalization Days in Transthyretin Amyloidosis Cardiomyopathy Patients.

In patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), tafamidis was associated with a lower rate of CV-related hospitalizations and a shorter stay. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an underdiagnosed disease characterized by deposits of improperly folded…
November 9, 2022